UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000053886 |
|---|---|
| Receipt number | R000061511 |
| Scientific Title | In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye |
| Date of disclosure of the study information | 2024/03/18 |
| Last modified on | 2025/03/31 17:26:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye
Acronym
In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye
Scientific Title
In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye
Scientific Title:Acronym
In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye
Region
| Japan |
Condition
Condition
Healthy adult volunteer
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
In an in vivo study of dynamic MR imaging of the human eye, we conduct data reanalysis focusing on both eye movement of the subjects and post-image processing to minimize ocular motion artifacts.
Basic objectives2
Others
Basic objectives -Others
In an in vivo study of dynamic MR imaging of the human eye, we conduct data reanalysis focusing on both eye movement of the subjects and post-image processing to minimize ocular motion artifacts.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Comparison of images before and after correction of eye movement using image processing, and evaluation of the validity of the numerical values obtained through correction analysis.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 40 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Healthy adults who have provided consent for secondary use were subjected to 1H-MR imaging as part of the clinical study 'Intraocular fluid dynamics measurement using O-17 stable isotope-labeled water in healthy adults' (jRCTs031210082) conducted from June 2021 to September 2021.
Key exclusion criteria
None
Target sample size
9
Research contact person
Name of lead principal investigator
| 1st name | Takayuki |
| Middle name | |
| Last name | Obata |
Organization
National Institutes for Quantum Science and Technology(QST)
Division name
Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science
Zip code
263-8555
Address
4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan
TEL
043-206-3230
obata.takayuki@qst.go.jp
Public contact
Name of contact person
| 1st name | Takayuki |
| Middle name | |
| Last name | Obata |
Organization
National Institutes for Quantum Science and Technology(QST)
Division name
Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science
Zip code
263-8555
Address
4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan
TEL
043-206-3230
Homepage URL
obata.takayuki@qst.go.jp
Sponsor or person
Institute
National Institutes for Quantum Science and Technology(QST)
Institute
Department
Personal name
Funding Source
Organization
Ministry of Education, Culture Sports, Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
National Institutes for Quantum Science and Technology Certified Review Board
Address
4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan
Tel
043-206-4706
helsinki@qst.go.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 03 | Month | 18 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
7
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2024 | Year | 02 | Month | 21 | Day |
Date of IRB
| 2024 | Year | 03 | Month | 12 | Day |
Anticipated trial start date
| 2024 | Year | 03 | Month | 18 | Day |
Last follow-up date
| 2025 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
observational study
Management information
Registered date
| 2024 | Year | 03 | Month | 18 | Day |
Last modified on
| 2025 | Year | 03 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061511
